Do you plan to offer adjuvant olaparib to all gBRCA+ breast cancer whether TNBC or HR+?

I offer adjuvant olaparib to germline BRCA mutated breast cancer patients (TNBC or hormone receptor positive and Her-2 negative) only if they meet the inclusion criteria that was used in the OlympiA study, which is as follows:

1) Patients with triple-negative breast cancer who were treated with adjuv...

I plan to offer adjuvant olaparib to all high risk gBRCA+ breast cancer given the benefit demonstrated in the ITT population of the OlympiA trial. These cancers are driven by the gBRCA mutation and there is no evidence that olaparib was less effective in HR+ patients. The subgroup analysis at median...

Currently, the data support treating all germline BRCA positive patients that are high risk (TNBC or HR+) with Olaparib in the adjuvant setting.